Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates

Antiviral Research

Volumn 80, Issue 2, 2008, Pages 194-199

  Bernardo, Lidice ^a   Izquierdo, Alienys ^a   Alvarez, Mayling ^a   Rosario, Delfina ^a   Prado, Irina ^a   López, Carlos ^b   Martínez, Rafael ^b   Castro, Jorge ^b   Santana, Emidalys ^a   Hermida, Lisset ^b   Guillen, Gerardo ^b   Guzmán, María G ^a  

^a INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

^b CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

Dengue 1; Domain III; Monkeys; Protection

Indexed keywords

ALUMINUM HYDROXIDE; FREUND ADJUVANT; RECOMBINANT PROTEIN; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DENGUE VIRUS; DRUG EFFICACY; IMMUNIZATION; IMMUNOGENICITY; MACACA; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; VIREMIA;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; BACTERIAL OUTER MEMBRANE PROTEINS; CELL LINE; CERCOPITHECUS AETHIOPS; CRICETINAE; DENGUE; DENGUE VACCINES; DENGUE VIRUS; HUMANS; MACACA; MACACA MULATTA; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; VERO CELLS; VIRAL ENVELOPE PROTEINS;

ANIMALIA; MACACA FASCICULARIS; MACACA MULATTA; NEISSERIA MENINGITIDIS; PRIMATES;

EID: 53449083630     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2008.06.005     Document Type: Article

References (50)

1. Alvarez M., Rodriguez-Roche R., Bernardo L., Morier L., and Guzman G. Improved dengue virus plaque formation on BHK21 and LLCMK2 cells: evaluation of some factors. Dengue Bull. 29 (2005) 1-9
2. Alvarez M., Rodriguez-Roche R., Bernardo L., Vázquez S., Morier L., Gonzalez D., Castro O., Kouri G., Halstead S.B., and Guzman M.G. Dengue hemorrhagic fever caused by sequential dengue 1-3 virus infections over a long time interval: Havana epidemic, 2001-2002. Am. J. Trop. Med. Hyg. 75 (2006) 1113-1117
3. Bernardo L., Izquierdo A., Prado I., Rosario D., Alvarez M., Santana E., Castro J., Martinez R., Rodriguez R., Morier L., Guillen G., and Guzman M.G. Primary and secondary infections of Macaca fascicularis monkeys with Asian and American genotypes of dengue virus 2. Clin Vaccine Immunol 15 3 (2008) 439-446
4. Blair P.J., Kochel T.J., Raviprakash K., Guevara C., Salazar M., Wu S.J., Olson J.G., and Porter K.R. Evaluation of immunity and protective efficacy of a dengue-3 pre-membrane and envelope DNA vaccine in Aotus nancymae monkeys. Vaccine 24 (2006) 1427-1432
5. Chin J.F., Chu J.J., and Ng M.L. The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry. Microbes Infect. 9 (2007) 1-6
6. De Paula S.O., and Lopes da Fonseca B.A. Optimizing dengue diagnosis by RT-PCR in IgM-positive samples: comparison of whole blood, buffy-coat and serum as clinical samples. J. Virol. Methods 102 (2002) 113-117
7. Durbin A.P., McArthur J.H., Marron J.A., Blaney J.E., Thumar B., Wanionek K., Murphy B.R., and Whitehead S.S. rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naive adults. Hum. Vaccin. 2 (2006) 255-260
8. Edelman R., Wasserman S.S., Bodison S.A., Putnak R.J., Eckels K.H., Tang D., Kanesa-Thasan N., Vaughn D.W., Innis B.L., and Sun W. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am. J. Trop. Med. Hyg. 69 (2003) 48-60
9. Endy T.P., Nisalak A., Chunsuttitwat S., Vaughn D.W., Green S., Ennis F.A., Rothman A.L., and Libraty D.H. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J. Infect. Dis. 189 (2004) 990-1000
10. Gubler D.J., and Clark G.G. Community-based integrated control of Aedes aegypti: a brief overview of current programs. Am. J. Trop. Med. Hyg. 50 (1994) 50-60
11. Guirakhoo F., Weltzin R., Chambers T.J., Zhang Z.X., Soike K., Ratterree M., Arroyo J., Georgakopoulos K., Catalan J., and Monath T.P. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J. Virol. 74 (2000) 5477-5485
12. Guzmán M.G., and Kourí G. Dengue: an update. Lancet Infect. Dis. 2 (2002) 33-42
13. Guzmán M.G., Rodríguez Roche R., Hermida L., Alvarez M., Lazo L., Mune M., Rosario D., Valdes K., Vazquez S., Martinez R., Serrano T., Paez J., Espinosa R., Pumariega T., and Guillen G. Induction of neutralizing antibodies and partial protection from viral challenge in Macaca fascicularis immunized with recombinant dengue 4 virus envelope glycoprotein expressed in Pichia pastoris. Am. J. Trop. Med. Hyg. 69 (2003) 129-134
14. Guzmán M.G., Alvarez M., Rodriguez-Roche R., Bernardo L., Montes T., Vazquez S., Morier L., Alvarez A., Gould E.A., Kourí G., and Halstead S. Neutralizing antibodies after infection with dengue 1 virus. Emerg. Infect. Dis. 13 (2006) 282-286
15. Halstead S.B., and Palumbo N.E. Studies on the immunization of monkeys against dengue. II. Protection following inoculation of combinations of viruses. Am. J. Trop. Med. Hyg. 22 (1973) 375-381
16. Halstead S.B., and O'Rourke E.J. Antibody-enhanced dengue virus infection in primate leukocytes. Nature 265 (1977) 739-741
17. Halstead S.B., and Deen J. The future of dengue vaccines. Lancet 360 (2002) 1243-1245
18. Halstead S.B., Shotwell H., and Casals J. Studies on the pathogenesis of dengue infection in monkeys. I. Clinical laboratory responses to primary infection. J. Infect. Dis. 128 (1973) 7-14
19. Hermida L., Rodríguez R., Lazo L., Bernardo L., Silva R., Zulueta A., López C., Martín J., Valdés I., del Rosario D., Guillén G., and Guzmán M.G. A fragment of the envelope protein from dengue-1 virus, fused in two different sites of the meningococcal P64k protein carrier, induces a functional immune response in mice. Biotechnol. Appl. Biochem. 39 (2004) 107-114
20. Hermida L., Rodríguez R., Lazo L., Silva R., Zulueta A., Chinea G., López C., Guzmán M.G., and Guillén G. A dengue-2 envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice. J. Virol. Methods 115 (2004) 41-49
21. Hermida L., Bernardo L., Martín J., Alvarez M., Prado I., López C., Sierra Bde L., Martínez R., Rodríguez R., Zulueta A., Pérez A.B., Lazo L., Rosario D., Guillén G., and Guzmán M.G. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 24 (2006) 3165-3171
22. Hombach J., Barrett A.D., Cardosa M.J., Deubel V., Guzman M., Kurane I., Roehrig J.T., Sabchareon A., and Kieny M.P. Review on flavivirus vaccine development. Proceedings of a Meeting Jointly Organised by the World Health Organization and the Thai Ministry of Public Health. Bangkok, Thailand, April 26-27, 2004. Vaccine 23 (2005) 2689-2695
23. Khanam S., Etemad B., Khanna N., and Swaminathan S. Induction of neutralizing antibodies specific to dengue virus serotypes 2 and 4 by a bivalent antigen composed of linked envelope domains III of these two serotypes. Am. J. Trop. Med. Hyg. 74 (2006) 266-277
24. Khanam S., Khanna N., and Swaminathan S. Induction of neutralizing antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors. Vaccine 24 (2006) 6513-6525
25. Khanam S., Rajendra P., Khanna N., and Swaminathan S. An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes. BMC Biotechnol. 7 (2007) 10
26. Koraka P., Benton S., van Amerongen G., Stittelaar K.J., and Osterhaus A.D.M.E. Efficacy of a live attenuated tetravalent candidate dengue vaccine in naïve and previously infected cynomolgus macaques. Vaccine 25 (2007) 5409-5416
27. Lanciotti R.S., Calisher C.H., Gubler D.J., Chang G.J., and Vorndam A.V. Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction. J. Clin. Microbiol. 30 (1992) 545-551
28. Lindblad E.B. Aluminium compounds for use in vaccines. Immunol. Cell Biol. 82 (2004) 497-505
29. Markoff L., Pang X., Houng H.S., Falgout B., Olsen R., Jones E., and Polo S. Derivation and characterization of a dengue type 1 host range-restricted mutant virus that is attenuated and highly immunogenic in monkeys. J. Virol. 76 (2002) 3318-3328
30. Men R.H., Bray M., and Lai C.J. Carboxy-terminally truncated dengue virus envelope glycoproteins expressed on the cell surface and secreted extracellularly exhibit increased immunogenicity in mice. J. Virol. 65 (1991) 1400-1407
31. Morens D.M., Halstead S.B., Repik P.M., Putvatana R., and Raybourne N. Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization. J. Clin. Microbiol. 22 (1985) 250-254
32. Mota J., Acosta M., Argotte R., Figueroa R., Mendez A., and Ramos C. Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein. Vaccine 23 (2005) 3469-3476
33. Muné M., Rodríguez R., Ramírez R., Soto Y., Sierra B., Rodríguez Roche R., Marquez G., Garcia J., Guillén G., and Guzmán M.G. Carboxy-terminally truncated Dengue 4 virus envelope glycoprotein expressed in Pichia pastoris induced neutralizing antibodies and resistance to Dengue 4 virus challenge in mice. Arch. Virol. 148 (2003) 2267-2273
34. Putnak R., Coller B.A., Voss G., Vaughn D.W., Clements D., Peters I., Bignami G., Houng H.S., Chen R.C., Barvir D.A., Seriwatana J., Cayphas S., Garçon N., Gheysen D., Kanesa-Thasan N., McDonell M., Humphreys T., Eckels K.H., Prieels J.P., and Innis B.L. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 23 (2005) 4442-4452
35. Putnak R., Feighny R., Burrous J., Cochran M., Hackett C., Smith G., and Hoke C. Dengue-1 virus envelope glycoprotein gene expressed in recombinant baculovirus elicits virus-neutralizing antibody in mice and protects them from virus challenge. Am. J. Trop. Med. Hyg. 45 (1991) 159-167
36. Raviprakash K., Porter K.R., Kochel T.J., Ewing D., Simmons M., Phillips I., Murphy G.S., Weiss W.R., and Hayes C.G. Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques. J. Gen. Virol. 81 (2000) 1659-1667
37. Raviprakash K., Ewing D., Simmons M., Porter K.R., Jones T.R., Hayes C.G., Stout R., and Murphy G.S. Needle-free Biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the GM-CSF gene increases immunogenicity and protection from virus challenge in Aotus monkeys. Virology 315 (2003) 345-352
38. Rodriguez-Roche R., Alvarez M., Guzmán M.G., Morier L., and Kourí G. Comparison of rapid centrifugation assay with conventional tissue culture method for isolation of dengue 2 virus in C6/36-HT cells. J. Clin. Microbiol. 38 (2000) 3508-3510
39. Rosario D., Alvarez M., Diaz J., Contreras R., Rodriguez R., Vazquez S., and Guzman M.G. Polymerase chain reaction for rapid detection and serotyping of dengue virus in clinical samples. Rev. Panam. Salud. Publica 4 (1998) 1-5
40. Rothman A.L. Dengue: defining protective versus pathologic immunity. J. Clin. Invest. 113 (2004) 946-951
41. Saluzzo J.F. Empirically derived live-attenuated vaccines against dengue and Japanese encephalitis. Adv. Virus Res. 61 (2003) 419-443
42. Sariol C.A., Muñoz-Jordán J.L., Abel K., Rosado L.C., Pantoja P., Giavedoni L., Rodriguez I.V., White L.J., Martínez M., Arana T., and Kraiselburd E.N. Transcriptional activation of interferon stimulated genes but not of cytokine genes after primary infection of rhesus macaques with dengue virus type 1. Clin. Vaccine Immunol. 14 (2007) 756-766
43. Simmons M., Nelson W.M., Wu S.J., and Hayes C.G. Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. Am. J. Trop. Med. Hyg. 58 (1998) 655-662
44. Simmons M., Murphy G.S., and Hayes C.G. Short report: antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. Am. J. Trop. Med. Hyg. 65 (2001) 159-161
45. Simmons M., Porter K.R., Hayes C.G., Vaughn D.W., and Putnak R. Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques. J. Virol. 80 (2006) 9577-9585
46. Srivastava A.K., Putnak J.R., Warren R.L., and Hoke Jr. C.H. Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection. Vaccine 13 (1995) 1251-1258
47. Sun W., Edelman R., Kanesa-Thasan N., Eckels K.H., Putnak J.R., King A.D., Houng H.S., Tang D., Scherer J.M., Hoke Jr. C.H., and Innis B.L. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am. J. Trop. Med. Hyg. 69 (2003) 24-31
48. Sun W., Nisalak A., Gettayacamin M., Eckels K.H., Putnak J.R., Vaughn D.W., Innis B.L., Thomas S.J., and Endy T.P. Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination. J. Infect. Dis. 193 (2006) 1658-1665
49. Velzing J., Groen J., Drouet M.T., van Amerongen G., Copra C., Osterhaus A.D., and Deubel V. Induction of protective immunity against Dengue virus type 2: comparison of candidate live attenuated and recombinant vaccines. Vaccine 17 (1999) 1312-1320
50. Zulueta A., Hermida L., Lazo L., Valdés I., Rodríguez R., López C., Silva R., Rosario D., Martín J., Guzmán M.G., and Guillén G. The fusion site of envelope fragments from each serotype of Dengue virus in the P64k protein, influence some parameters of the resulting chimeric constructs. Biochem. Biophys. Res. Commun. 308 (2003) 619-626